Customize your JAMA Network experience by selecting one or more topics from the list below.
Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
The US Preventive Services Task Force (USPSTF) has published updated recommendations on screening for chronic obstructive pulmonary disease (COPD).
Chronic obstructive pulmonary disease is a serious lung disease that affects the ability to breathe. In people with COPD, the airways inside the lungs are damaged and narrowed, causing problems with airflow in and out of the lungs. Common symptoms of COPD include shortness of breath, wheezing, and coughing. Two types of COPD are chronic bronchitis and emphysema. Asthma is another type of obstructive lung disease that has some overlap with COPD, but unlike asthma, lung changes that happen in COPD are not reversible. The most common cause of COPD is smoking, and the best way to prevent COPD in people who smoke is to stop smoking. The April 5, 2016, issue of JAMA contains the updated USPSTF recommendations about screening for COPD.
Screening for COPD can be done with a questionnaire about COPD risk factors, which, if it shows a high risk of COPD, is followed by diagnostic testing with spirometry. Spirometry tests for how well the lungs work by measuring how much air is inhaled and exhaled and how quickly it is exhaled, both before and after treatment with a type of inhaled medication called a bronchodilator. Another option is to do screening spirometry without a bronchodilator, followed by diagnostic spirometry if the screening test result is abnormal.
The USPSTF recommendation applies to adults who do not have any signs or symptoms of breathing problems. It does not apply to adults who may need preoperative testing for lung disease because they have a high risk of lung complications related to surgery.
There are currently no studies on the benefits and harms of finding COPD in people who do not report symptoms of the disease. In people with known COPD, there is evidence that treatment with inhalers decreases COPD exacerbations (symptom flares). However, even in people with known COPD, studies have not shown consistent benefits of treatment on mortality or quality of life. Potential harms of treatment include side effects from using inhaled medications, although these are generally mild. Another factor is the time and cost of conducting both screening and diagnostic spirometry.
Given the lack of evidence on the effects of screening in adults with no symptoms of COPD on health outcomes, the USPSTF has concluded that there is no net benefit to screening for COPD.
The USPSTF concludes that screening for COPD is not recommended in adults who do not have symptoms suggestive of COPD (called a “D” statement).
National Heart, Lung, and Blood Institutewww.nhlbi.nih.gov/health/health-topics/topics/copd
US Preventive Services Task Forcewww.uspreventiveservicestaskforce.org
To find this and previous JAMA Patient Pages, go to the Patient Page link on JAMA’s website at www.jama.com. Spanish translations are available in the supplemental content tab. A Patient Page on diagnosis and treatment of COPD was published in the September 26, 2012, issue of JAMA.
Source: US Preventive Services Task Force. Screening for chronic obstructive pulmonary disease: US Preventive Services Task Force recommendation statement. JAMA. doi:10.1001/jama.2016.2638.
Topic: Preventive Medicine
Jin J. Screening for Chronic Obstructive Pulmonary Disease. JAMA. 2016;315(13):1419. doi:10.1001/jama.2016.3322